Signal brief

Topline Phase 3 results showing PFS and OS improvements materially expand Ziihera's commercial opportunity beyond its current second‑line biliary tract approval. An sBLA submission and intended NCCN adoption create a credible path to first‑line GEA revenue, driving upside to Jazz's oncology sales, royalties, and long‑term cash flows. Historical precedent: positive pivotal readouts and label expansions (for example, pembrolizumab and other checkpoint inhibitor label expansions) produced sustained revenue growth and re‑rating for underlying partners, while initial toplines have frequently produced near‑term share price pops for collaborators. Risks remain: full dataset review, regulatory scrutiny, competitive HER2 agents, and execution of commercialization can temper upside; mid‑2026 additional OS analysis could modify the story. Taken together, the balance of likely incremental revenue and milestone timing supports a bullish view rather than unequivocal euphoria.